ATIM-19. POPULATION PHARMACOKINETIC (PPK) ANALYSIS OF NIVOLUMAB FLAT AND WEIGHT-BASED DOSING REGIMENS AND ASSOCIATIONS WITH SAFETY IN PATIENTS WITH RECURRENT GLIOBLASTOMA (rGBM) TREATED IN CHECKMATE 143

BACKGROUND: Nivolumab 3 mg/kg Q2W was well tolerated in rGBM in CheckMate 143 (NCT02017717). It is unknown if nivolumab PK will differ in rGBM vs other tumor types; therefore, a PPK analysis was performed to compare nivolumab PK in patients with rGBM vs those with NSCLC. Additionally, this analysis...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Shen, Jun, Hruska, Matthew, Zwirtes, Ricardo, Potter, Von, Paliwal, Prashni, Roy, Amit, Bello, Akintunde, Suryawanshi, Satyendra, Lim, Michael
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2017
Assuntos:
Abstracts
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5692350/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.114
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados